Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label proof-of-concept study of LFG316 in PNH with switch to LNP023
jRCT2080223041Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of tesidolumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: Efficacy (serum LDH reduction). Started Dec 2015; status: completed.
02
Drugs
tesidolumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2080223041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223041.